Funding crunch threatens ARV rollout
The World Bank’s Multi-Country HIV/AIDS Programme (MAP) is in the last 10 months of its six-year run in the DRC. The US President’s Emergency Plan for AIDS Relief, PEPFAR, which has been providing medication for opportunistic infections and laboratory support, is expected to halt this aid, while the international funding mechanism, UNITAID, which has been providing second-line medication and paediatric ARVs, is withdrawing in 2011.
That leaves the Global Fund to fight AIDS, Tuberculosis and Malaria as the only donor for HIV treatment in the country.
Yves Nicolas Alexandre, head of the UN Development Programme’s Global Fund Programme Management Unit in the DRC, acknowledged that while the Global Fund’s programmes are still treating new patients, the end of the World Bank’s MAP project has put pressure on the Fund.
Only 10 percent of people ‘ 35,000 people ‘ in the DRC who need ARVs have access to them, Corinne Benazech, coordinator of the HIV/AIDS project for the medical charity, Médecins Sans Frontières, told IRIN/PlusNews. “The main reason for the low numbers on treatment is lack of funding,” she noted.
“We are very worried about this situation; raising money has not been easy,” said Adama Guindo, country representative for UNDP, which is the Global Fund’s principal recipient for HIV grants for rounds three, seven and eight. “Most bilateral donors tell us that they donate funds for HIV through the Global Fund and do not want to do parallel funding – the government must put in more effort towards resource mobilization.”
In future, ‘the priority would be to put in place a more effective donor coordination to ensure that the ARVs are distributed in areas where the capacity for treating patients is already developed”, a World Bank spokesperson told IRIN/PlusNews.
According to MSF’s Benazech, some programmes in the capital are no longer accepting new patients for HIV treatment.
“Many patients coming from the government hospital, which has run out of drugs, arrive at the MSF clinic when they are already extremely weak and close to death so their chances of survival are low,” she said. “Patients on treatment are forced to pay for the CD-4 examination [which measures immune strength] follow-up… which is extremely expensive for the average Congolese person.
“HIV in the DRC is not chronic, like it is in many other African countries, where significant coverage is being reached; here it is acute,” she added. “We urgently need more advocacy and mobilization for additional funding for treatment in the DRC; the situation is critical.”
This feature is used with permission from IRIN/PlusNews –www.plusnews.org
Author
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
View all posts
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Funding crunch threatens ARV rollout
by Health-e News, Health-e News
April 19, 2010